NeOnc Technologies Holdings (NTHI) Registration filing summary

Company overview and business model

• Clinical-stage biopharmaceutical company focused on novel drug delivery for brain cancers and CNS diseases.

• Lead products are NEO100 (intranasal perillyl alcohol) and NEO212 (oral/intranasal temozolomide conjugate), targeting glioblastoma and brain metastases.

• NEO100 is in Phase IIa trials for recurrent malignant glioma and meningioma; NEO212 has begun Phase I/II trials.

• Pipeline includes additional CNS and oncology indications, including pediatric brain tumors and Parkinson’s disease.

• No commercial products or sales infrastructure; revenue to date is from humanitarian use and licensing.

Financial performance and metrics

• Net losses: $9.6M (nine months ended Sep 30, 2024), $14.9M (2023), $3.0M (2022); accumulated deficit of $48.4M as of Sep 30, 2024.

• Revenue: $63K (nine months ended Sep 30, 2024), $70K (2023), $20K (2022), all from non-product sales.

• Cash and equivalents: $1.3M as of Sep 30, 2024; shareholders’ deficit: $5.3M.

• Raised $17.7M in equity and $11.7M in notes payable since inception; recent private placements at $12–$16/share.

• Auditor’s report includes a going concern warning due to recurring losses and limited cash.

Use of proceeds and capital allocation

• Company will not receive proceeds from the resale of registered shares in the direct listing.

• Proceeds from recent private placements ($10M) to be used for R&D, clinical trials, and general operations.

• Ongoing need for substantial additional funding to support operations and product development.